After a year of RFK Jr.’s policies, public health hangs in the balance | Editorial

U.S. measles vaccination rates are declining, with Pennsylvania, New Jersey and Delaware slipping below the CDC’s 95% herd‑immunity threshold; a South Carolina outbreak has sickened nearly 1,000 people and two children in Texas died last year. CDC data indicate more than 90% of infections occur in people who are unvaccinated or have unknown inoculation status, a group that makes up under 10% of the population. Policy changes under HHS Secretary Robert F. Kennedy Jr.—including fewer recommended childhood vaccinations and efforts to overturn state mandates—raise regulatory and public‑health risks that could increase healthcare utilization, local school and workforce disruptions, and government response costs.

Analysis

Market structure: Falling childhood vaccination rates (PA/NJ/DE <95%; SC outbreak ~1,000 cases) reallocates near-term demand from routine vaccine manufacturers toward diagnostics, acute care and supply-chain distributors. Winners: distributors (AmerisourceBergen ABC, McKesson MCK), diagnostics and consumables (Becton Dickinson BDX, Abbott ABT, Thermo Fisher TMO), emergency-room heavy hospitals (HCA). Losers: pediatric vaccine revenue lines at large pharmas (Merck MRK, Pfizer PFE) could see modest volume pressure; pricing power shifts to distributors and urgent-care providers during outbreaks.

Risk assessment: Tail risks include a national policy reversal mandating emergency vaccination campaigns (sharp upside demand) or litigation/regulatory instability under current HHS leadership (supply-chain hesitancy). Time horizons: immediate (days) – headline-driven volatility; short-term (weeks–3 months) – state outbreaks and procurement orders; long-term (quarters–years) – potential permanent erosion of pediatric coverage below herd immunity thresholds (92–95%) that raise recurrent outbreak risk. Hidden dependencies: school-mandate lawsuits, state budget reallocations, and federal emergency funding decisions.

Trade implications: Favor long positions in distributors/diagnostics for 3–12 months (expect 10–25% upside if outbreaks widen) and use limited-duration put spreads on MRK/PFE to hedge vaccine-exposure. Consider pair trades: long MCK/ABC vs short MRK to capture distribution margin gains vs vaccine volume risk. Use options to buy convexity around CDC/ACIP announcements (3–6 month expiries).

Contrarian angles: Consensus underestimates pharma diversification — vaccine lines are often <10–15% of MRK/PFE revenue, so broad sell-offs may be overdone and present tactical call opportunities if emergency campaigns are approved. Historical parallels (measles rebounds) show policy whipsawing; a sharp outbreak could quickly restore mandates and spike vaccine orders, creating a mean-reversion trade into beaten-up vaccine names within 6–12 months.

Key Decisions for Investors

• Establish a 2–3% portfolio long split between BDX and ABT (1–1.5% each) within 30 days to capture testing/consumable demand; target +15% price appreciation over 3–9 months if outbreaks expand; trim if CDC issues new universal pediatric guidance reversing decline.
• Initiate a 1% notional 3–6 month put spread on MRK (buy 15% OTM puts, sell 7.5% OTM puts) as a hedged short against pediatric vaccine volume risk; increase to 2% notional if >3 US states report vaccination rates below 92% or national cases exceed 2,000.
• Open a 1–2% pair trade: long 1% MCK (or ABC) equity / short 0.5–1% MRK equity to play distributor margin expansion versus vaccine revenue softness; add exposure if state procurement contracts are announced (observable via SEC filings or state press releases within 30 days).
• Reduce exposure to long-duration municipal bonds issued by PA/NJ/DE by 1–3% and reallocate to high-quality corporates or short-term cash within 60 days to hedge potential state budget pressure from outbreak response; restore allocation only if state budgets receive targeted federal relief.